The purpose of this study is to investigate the effects of an external heat flux applied to a bifurcated artery which surrounded by the human tissue during thermal therapy. Two different 2D models have simulated, first the bifurcated artery, and second the stenosed bifurcated artery with two symmetrical stenosis. This study helps a lot to determinate the principal data for achieving the goal of experimental simulation. Three different external heat fluxes, three different durations and different physical properties have been investigated. Non-dimensional blood and tissue temperatures were plotted against the longitudinal and transverse coordinates. Some dynamic and physical properties of the flow and the tissue were investigated. Simulation results show that the amount of external heat flux, the porosity, and the heating period are the crucial factors determining the distribution of thermal dose for thermal therapy. It can be concluded that by applying the optimum values observed, the critical values of velocity, tissue and blood temperatures for different location along the longitudinal axis, in order to cure cancer cells in thermal therapy in existence of stenosis, achieved.
Following an introductory overview, Hyperthermia In Cancer Treatment: A Primer comprehensively describes the biological reasons for associating hyperthermia with radiation and chemotherapy and the biological and clinical effects of hyperthermia on cancerous and normal tissues. The volume’s 20 chapters are arranged in three principal parts: physical and methodological studies, biologic principles, and clinical studies.
The 41st Annual International Conference of the IEEE EMBS, took place between July 23 and 27, 2019, in Berlin, Germany. The focus was on "Biomedical engineering ranging from wellness to intensive care." This conference provided an opportunity for researchers from academia and industry to discuss a variety of topics relevant to EMBS and hosted the 4th Annual Invited Session on Computational Human Models. At this session, a bevy of research related to the development of human phantoms was presented, together with a substantial variety of practical applications explored through simulation.
Oncothermia is the next generation medical innovation that delivers selective, controlled and deep energy for cancer treatment. The basic principles for oncothermia stem from oncological hyperthermia, the oldest approach to treating cancer. Nevertheless, hyperthermia has been wrought with significant controversy, mostly stemming from shortcomings of controlled energy delivery. Oncothermia has been able to overcome these insufficiencies and prove to be a controlled, safe and efficacious treatment option. This book is the first attempt to elucidate the theory and practice of oncothermia, based on rigorous mathematical and biophysical analysis, not centered on the temperature increase. It is supported by numerous in-vitro and in-vivo findings and twenty years of clinical experience. This book will help scientists, researchers and medical practitioners in understanding the scientific and conceptual underpinnings of oncothermia and will add another valuable tool in the fight against cancer. Professor Andras Szasz is the inventor of oncothermia and the Head of St Istvan University's Biotechnics Department in Hungary. He has published over 300 papers and lectured at various universities around the world. Dr. Oliver Szasz is the managing director of Oncotherm, the global manufacturer and distributor of medical devices for cancer treatment used in Europe & Asia since the late 1980s. Dr. Nora Szasz is currently a management consultant in healthcare for McKinsey & Co.
Background: Despite advances in treatment options, prostate cancer remains the second-most diagnosed and second leading cause of cancer-related death in men in the United States. The efficacy of conventional anti-cancer treatments is dependent, in part, on tumor blood flow and oxygenation. Tumor vasculature is abnormal relative to healthy tissue, leading to reduced blood flow and oxygen delivery, and thus, treatment resistance. An emerging adjuvant to conventional treatment to overcome resistance to radiation is heat therapy. While heat therapy may sensitize tumors to radiation via increases in tumor blood flow and thus, oxygenation, we hypothesized that heat-induced radiosensitization occurs independent, in part, of tumor blood flow or oxygenation. Methods: Clonogenic cell survival and cell viability were assessed using human prostate cancer (PC-3) cells in vitro. Individual tissue culture flasks of PC-3 cells were randomized into 6 groups, normothermic non-radiated (NT-NR, n=8), normothermic radiated (NT-R, n=8), acute hyperthermic non-radiated (HTA-NR, n=8), acute hyperthermic radiated (HTA-R, n=8), chronic (repeated) hyperthermic non-radiated (HTC-NR, n=8), and chronic (repeated) hyperthermic radiated (HTC-R, n=8) for both clonogenic cell survival and cell viability assays. For assessment of both clonogenic cell survival and cell viability, NT-NR and NT-R flasks were maintained in an incubator at 37° C for the duration of the experiment. HTA-NR and HTA-R flasks were maintained in an incubator at 37° C and heated in a separate incubator to 41° C for 60 minutes prior to radiation. HTC-NR and HTC-R flasks were maintained at 37o C and heated to 41o C for 60 minutes every 48 hours for 3 heat treatments. Non-radiated flasks were subjected to 0 Gy radiation, while radiated flasks were subjected to 2 Gy radiation. For clonogenic cell survival, cells were then plated in 60 mm tissue culture dishes at a density of 500 cells/plate and 1000 cells/plate in 5 replicates each per flask and allowed to grow for 8 days in an incubator at 37° C. Cell survival was assessed via counting the number of fixed and stained colonies >50 cells at the completion of 8 days of incubation. For cell viability, cells were plated into 96-well plates and incubated for 24, 48, and 72 hours before addition of MTT reagent for quantification of absorbance. Data are presented as mean ± SEM. Results: Clonogenic cell survival was significantly reduced between NT-NR vs. NT-R, HTA-NR, HTA-R, and HTC-R (100 % ± 9.7% vs. 59.1 % ± 5.9 %, 72.4% ± 8.5%, 40.3% ± 3.1%, and 43.3% ± 3.4%, respectively; p
Since the first observations of Busch in 1866, the possible use of heat as a therapeutic agent in the cure of cancer has been repeatedly subject to bursts of interest, almost invariably followed by periods of neglect and skepticism. In 1963-1964, this problem was again attacked by us both from the biochemical and from the clinical points of view. The first results of this joint effort were positive beyond expectation, and generated a new revial of studies aimed at the identification of the nature of the bio chemical lesion as well as at the optimization of technique and of the therapeutic schedules connected with clinical use. Although the number of mammalian tumors which have been proved to be heat-sensitive is now relatively large, and although in some cases a correlation has been demonstrated between tumorigenicity and heat-sensitivity of in vitro cultured cell lines, the question of a direct and constant relationship between neoplastic character and higher sensitivity to hyperthermic exposure is still open to continuing investigation and reappraisal. Several studies deal in fact with the determination of the conditions under which, in vitro and or in vivo, different tumors are efficiently damaged by elevated temperatures.
Heat shock proteins are emerging as important molecules in the development of cancer and as key targets in cancer therapy. These proteins enhance the growth of cancer cells and protect tumors from treatments such as drugs or surgery. However, new drugs have recently been developed particularly those targeting heat shock protein 90. As heat shock protein 90 functions to stabilize many of the oncogenes and growth promoting proteins in cancer cells, such drugs have broad specificity in many types of cancer cell and offer the possibility of evading the development of resistance through point mutation or use of compensatory pathways. Heat shock proteins have a further property that makes them tempting targets in cancer immunotherapy. These proteins have the ability to induce an inflammatory response when released in tumors and to carry tumor antigens to antigen presenting cells. They have thus become important components of anticancer vaccines. Overall, heat shock proteins are important new targets in molecular cancer therapy and can be approached in a number of contrasting approaches to therapy.
Hyperthermia has been found to be of great benefit in combination with radiation therapy or chemotherapy in the management of patients with difficult and com plicated tumor problems. It has been demonstrated to increase the efficacy, of ionising radiation when used locally but also has been of help in combination with systemic chemotherapy where hyperthermia is carried out to the total body. Problems remain with regard to maximizing the effects of hyperthermia as in fluenced by blood flow, heat loss, etc. The present volume defines the current knowledge relative to hyperthermia with radiation therapy and/or chemotherapy, giving a comprehensive overview of its use in cancer management. Philadelphia/Hamburg, June 1995 L.W. BRADY H.-P. HEILMANN Preface In an attempt to overcome tumor resistance, hypoxia, or unfavorable tumor condi tions, oncological research has come to focus on gene therapy, immunotherapy, new cytotoxic agents, and increasingly sophisticated radiotherapy. Radiation research has been directed towards heavy particle therapy and modification of the radiation response by either protecting or sensitizing agents. Improved dose localization using rotational or conformal strategies has also been implemented. Recently, changes in radiation fractionation schedules have shown promise of better results. Hyperthermia in cancer therapy can be viewed similarly as another means to increase the sensitivity of tumors to radio- and chemotherapy.
